Recent News
ASBM Comments on CMS Medicare – Price Negotiation Guidance
April 14, 2023 Re: Medicare Drug Price Negotiation Program GuidanceSubmitted via email to: IRARebateandNegotiation@cms.hhs.gov Dear Sir or Madam, Thank you for the opportunity to provide comments on the initial guidance memorandum regarding implementation of the Medicare Drug Price Negotiation Program. The Alliance for Safe Biologic Medicines...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
CMS Doubles Down on Medicare Drug Price Controls, Threatening Patient Access and Innovation
The Centers for Medicare & Medicaid Services (CMS) has announced an additional 15 drugs that will be subject to price controls under the Inflation Reduction Act (IRA). This expansion continues a flawed policy that threatens innovation and jeopardizes patient access to critical treatments, including drugs vital for cancer treatment and popular new weight loss medications that have transformed the management of obesity and related conditions.
ASBM Comments to CMS Opposing IRA’s Medicare Part D Redesign
“It is ASBM’s position that patients should have access to innovative medicines, and that biosimilars are an important tool to expand access by creating cost savings through market competition.”